We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
More than 20 leading drugmakers have teamed up on a new program to develop innovative antibiotics in the coming decade to help curb the global threat of antibiotic-resistant infections. Read More
A new clinical trial network formed by the National Institute of Allergy and Infectious Diseases (NIAID) aims to accelerate COVID-19 vaccine research by using a standardized protocol to test multiple vaccine candidates, allowing results of the trials to be compared more easily. Read More
Merck and Eisai have received a complete response letter (CRL) from the FDA for Keytruda (pembrolizumab) plus Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Read More
Chinese drugmaker Clover Biopharmaceuticals has received a $66 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) to support clinical development and manufacturing of its candidate COVID-19 vaccine. Read More
The dual antibody cocktail entered a phase 3 trial this week to assess its ability to prevent infection among people exposed to coronavirus patients. Read More
RSS
